Details for New Drug Application (NDA): 076643
✉ Email this page to a colleague
NDA 076643 describes CARBILEV, which is a drug marketed by Ranbaxy and is included in one NDA. Additional details are available on the CARBILEV profile page.
The generic ingredient in CARBILEV is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.
The generic ingredient in CARBILEV is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.
Summary for 076643
| Tradename: | CARBILEV |
| Applicant: | Ranbaxy |
| Ingredient: | carbidopa; levodopa |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, FOR SUSPENSION;ORAL | Strength | 10MG;100MG | ||||
| Approval Date: | Jun 10, 2005 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, FOR SUSPENSION;ORAL | Strength | 25MG;100MG | ||||
| Approval Date: | Jun 10, 2005 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, FOR SUSPENSION;ORAL | Strength | 25MG;250MG | ||||
| Approval Date: | Jun 10, 2005 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
